Integrating Your Drug Strategy Within a Solid Foundation for Success

Sep 2019

Demand for drugs and therapeutics is growing thanks to the globalization of pharmaceutical-based medicine. Manufacturing new drugs and getting them to market faster, more economically and safely demands development strategies and business models that support successful outcomes for both investors and patients.

Outsourcing has become an increasingly attractive business model for pharma as companies seek partners who can deliver comprehensive end-to-end drug substance and drug product development. It has prompted contract manufacturing organizations (CMOs) to consolidate and expand to create the more comprehensive contract development and manufacturing organization (CDMO). Since then, the CDMO model has evolved and a new class of CDMO has emerged; the embedded CDMO

In this whitepaper, we look at the broad set of trends influencing pharmaceutical development and manufacturing strategy today, and how these drivers are influencing new business models with outsourced partners. We highlight the inherent value proposition of embedded CDMOs, and how this business model is helping to optimize drug substance and drug product development and commercial manufacture.



You can download the full white paper by completing the form below.

Pfizer CentreOne would like to send you information which we believe may be of value to you and relevant to your work. If you would like to receive such information, please tick the box below.